Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10589360rdf:typepubmed:Citationlld:pubmed
pubmed-article:10589360lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10589360lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:10589360lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:10589360lifeskim:mentionsumls-concept:C0009429lld:lifeskim
pubmed-article:10589360lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:10589360lifeskim:mentionsumls-concept:C0063041lld:lifeskim
pubmed-article:10589360lifeskim:mentionsumls-concept:C0556895lld:lifeskim
pubmed-article:10589360pubmed:issue6 Suppl 18lld:pubmed
pubmed-article:10589360pubmed:dateCreated2000-1-5lld:pubmed
pubmed-article:10589360pubmed:abstractTextAn open-label, one-year study was conducted to evaluate the safety and clinical response to leflunomide and methotrexate combination therapy for rheumatoid arthritis. Study results revealed tolerable safety, no significant pharmacokinetic interactions between methotrexate and leflunomide, and suggested improved clinical response with combination therapy.lld:pubmed
pubmed-article:10589360pubmed:languageenglld:pubmed
pubmed-article:10589360pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10589360pubmed:citationSubsetIMlld:pubmed
pubmed-article:10589360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10589360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10589360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10589360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10589360pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10589360pubmed:statusMEDLINElld:pubmed
pubmed-article:10589360pubmed:issn0392-856Xlld:pubmed
pubmed-article:10589360pubmed:authorpubmed-author:KremerJ MJMlld:pubmed
pubmed-article:10589360pubmed:authorpubmed-author:WeinblattM...lld:pubmed
pubmed-article:10589360pubmed:authorpubmed-author:MroczkowskiP...lld:pubmed
pubmed-article:10589360pubmed:issnTypePrintlld:pubmed
pubmed-article:10589360pubmed:volume17lld:pubmed
pubmed-article:10589360pubmed:ownerNLMlld:pubmed
pubmed-article:10589360pubmed:authorsCompleteYlld:pubmed
pubmed-article:10589360pubmed:paginationS66-8lld:pubmed
pubmed-article:10589360pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:meshHeadingpubmed-meshheading:10589360...lld:pubmed
pubmed-article:10589360pubmed:articleTitleMethotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis.lld:pubmed
pubmed-article:10589360pubmed:affiliationDivision of Rheumatology, Albany Medical College, New York 12208-3479, USA.lld:pubmed
pubmed-article:10589360pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10589360pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10589360lld:pubmed